Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis
Conditions
Keywords
Post Pneumonectomy Patients, IPF, COPD
Brief summary
* Pulmonary diseases are increasingly important causes of morbidity and mortality in the modern world. * Sildenafil, an orally administered a phosphodiesterase type 5 (PDE-5) inhibitor, targets the nitric oxide (NO) pathway. The drug was first approved for the treatment of Pulmonary Arterial Hypertension (PAH) in 2005. * The aim of the suggested study is to examine the acute effect of oral intake of sildenafil on exercise tolerance and functional capacity in Chronic Obstructive Pulmonary Disease (COPD), Idiopathic pulmonary fibrosis (IPF) and post Pneumonectomy patients. * The investigators hypothesize that oral ingestion of sildenafil prior the exercise may enhance exercise tolerance and improve function in COPD, IPF and post Pneumonectomy patients. * Patients and Methods: Sixty chronic lung disease patients males and females (aged 30 to 90 years) 20 COPD (GOLD III-IV) \[9, 39\] , 20 IPF and 20 post Pneumonectomy patients will be recruit to this study. * All subjects will carried out two maximal cardiopulmonary exercise tests (CPET) on bicycle ergometer in different days; 60 min after intake of placebo and 60 min after intake of 100 mg sildenafil (Pfizer, Sandwich, UK), in random order. * In first meeting prior exercise test at rest standard pulmonary function test, diffusion of CO, TLC and RV will be measured. In addition, Doppler Echocardiography and blood samples for NT-proBNP will be taken prior and post each CPET. * After 15-20 minute of passive recovery post exercise test all patients will perform 3 short functional tests including 6 minute walk test to assess functional capacity.
Interventions
DRUGSildenafil
Acute single dose of 100 mg of sildenafil. Oral intake in tablet form.
Sponsors
Rabin Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
30 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with severe COPD GOLD stage III- IV, FEV1 30-50% or less of predicted values, greater shortness of breath, reduced exercise capacity, repeated excretions and\\ or with chronic respiratory failure \[9, 39\]. 2. IPF patients diagnosed essentially according to the American Thoracic and European Respiratory Societies (ATS-ERS) by clinical diagnostic criteria of: (a) High-resolution computed tomography (HRCT) demonstrating a pattern of confident or possible IPF (b) Abnormal pulmonary physiology with evidence of restriction and/or impaired gas exchange (can exist during exercise alone) (c) Exclusion of other known causes of interstitial lung disease (e.g.: connective tissue disease, environmental exposure,etc.)\[31\]. 3. Patients post Pneumonectomy more than 6 month from the amputation surgery for any diagnosis (Cancer, Trauma, and Infection- Bronchiectasis).
Exclusion criteria
1. Patients with known sensitivity or contraindications to phosphodiesterase 5 (PDE-5) inhibitor therapies will be excluding from the study. 2. Thromboembolic disease will be excluded by pulmonary CT-angiography or perfusion scan. 3. Patients with a history of left-sided heart failure will be excluded. 4. Patients will also exclude if they are on regular treatment with nitrates or PDE-5 inhibitors (Sildenafil, Tadalafil, Vardenafil).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| VO2 Peak | 2-30 days between exercise tests | — |
| 6 min walk test | 2-30 days between exercise tests | Distance walked in 6 min test |
| Functional Tests | 2-30 days between exercise tests | 1. 30 seconds chair stand test- number of repetitions in 30 sec 2. 8-ft-up-and -go (agility and coordination)- number of sec that takes to complete the task. |
Secondary
| Measure | Time frame |
|---|---|
| Pulmonary Arterial Pressure | 2-30 days between exercise tests |
| NT-pro-BNP | 2-30 days between exercise tests |
Countries
Israel
Outcome results
None listed